Tasadenoturev - DNAtrix/University of Texas M. D. Anderson Cancer Center
Alternative Names: Ad-delta24-RGD; Ad-DNX 2401; Ad5-Delta 24RGD; Ad5-delta24-RGD; Adenovirus DNX 2401; Adenovirus-5 delta 24 RGD; Delta 24 RGD 4C; Delta-24-RGD; Delta-24-RGD-H43m; DNX 2401; IE-CRAd; RGD-delta24; TasadenoturevLatest Information Update: 10 Nov 2023
At a glance
- Originator DNAtrix; University of Texas M. D. Anderson Cancer Center
- Developer Alcyone Therapeutics; Clinica Universidad de Navarra; DNAtrix; Merck & Co; University of Alabama Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma
- Phase I Diffuse intrinsic pontine glioma
- Preclinical Rhabdoid tumour; Teratoma
- No development reported Gliosarcoma; Ovarian cancer
Most Recent Events
- 20 Sep 2023 Pharmacodynamics data from a phase-I trial in Glioblastoma presented at the Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2023)
- 20 Sep 2023 Pharmacodynamics data from a preclinical trial in Glioblastoma presented at the Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2023)
- 11 Apr 2023 Phase-I development is ongoing in Diffuse intrinsic pontine glioma(First-line therapy, In adolescents, In children, In infants) in Spain (Intratumoural, Injection) (DNAtrix Pipeline, April 2023)